Last reviewed · How we verify
Receptor Agonists (GLP1RA)
GLP-1 receptor agonists activate glucagon-like peptide-1 receptors to stimulate insulin secretion, suppress glucagon, and slow gastric emptying, thereby lowering blood glucose levels.
GLP-1 receptor agonists activate glucagon-like peptide-1 receptors to stimulate insulin secretion, suppress glucagon, and slow gastric emptying, thereby lowering blood glucose levels. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Receptor Agonists (GLP1RA) |
|---|---|
| Sponsor | Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
GLP-1 receptor agonists bind to and activate GLP-1 receptors on pancreatic beta cells, enhancing glucose-dependent insulin secretion. They simultaneously inhibit glucagon release from alpha cells and delay gastric emptying, reducing postprandial glucose excursions. These agents also promote satiety and may have cardiovascular and weight loss benefits.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Abdominal pain
- Hypoglycemia
Key clinical trials
- Residual Gastric Content After Holding of Glucagon-like Peptide-1 Receptor Agonists Before Elective Surgery
- Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD
- Impact of Discontinuing GLP-1 Receptor Agonists for Two Weeks Prior to Upper Endoscopy on the Risk of Gastric Retention
- Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control (PHASE4)
- Comparison of Type 2 Diabetes Pharmacotherapy Regimens
- Cardiovascular and Endothelial Markers During OGTT Before and at Six and Twelve Months Post-treatment in Women With PCOS
- Comparison of Body Composition Changes With Weight Loss Interventions
- Association of Gene Polymorphism With Susceptibility to T2DM and the Therapeutic Responses to Exenatide in Chinese Patients With T2DM (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: